These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 38564776)

  • 1. Immune status and selection of patients for immunotherapy in myeloma: a proposal.
    Dhodapkar MV
    Blood Adv; 2024 May; 8(10):2424-2432. PubMed ID: 38564776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune therapy in multiple myeloma.
    Luptakova K; Avigan D
    Clin Adv Hematol Oncol; 2015 Nov; 13(11):767-75. PubMed ID: 27058703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma.
    Lee SJ; Borrello I
    Cancer Treat Res; 2016; 169():207-225. PubMed ID: 27696265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-based therapies in the management of multiple myeloma.
    Zanwar S; Nandakumar B; Kumar S
    Blood Cancer J; 2020 Aug; 10(8):84. PubMed ID: 32829378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Therapies in Multiple Myeloma.
    Kumar SK; Anderson KC
    Clin Cancer Res; 2016 Nov; 22(22):5453-5460. PubMed ID: 28151713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in multiple myeloma: when, where, and for who?
    Verkleij CPM; Korst CLBM; van de Donk NWCJ
    Curr Opin Oncol; 2020 Nov; 32(6):664-671. PubMed ID: 32852308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in immunotherapy in multiple myeloma.
    Boussi L; Niesvizky R
    Curr Opin Oncol; 2017 Nov; 29(6):460-466. PubMed ID: 28877078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.
    Su CT; Ye JC
    J Hematol Oncol; 2021 Jul; 14(1):115. PubMed ID: 34301270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
    Anderson LD; Dhakal B; Jain T; Oluwole OO; Shah GL; Sidana S; Perales MA; Pasquini MC
    Transplant Cell Ther; 2024 Jan; 30(1):17-37. PubMed ID: 37913909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies.
    Hoyos V; Borrello I
    Blood; 2016 Sep; 128(13):1679-87. PubMed ID: 27506540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
    Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F
    Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for the treatment of multiple myeloma.
    Jung SH; Lee HJ; Vo MC; Kim HJ; Lee JJ
    Crit Rev Oncol Hematol; 2017 Mar; 111():87-93. PubMed ID: 28259300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapeutic approaches to treat multiple myeloma.
    Roeven MW; Hobo W; Schaap N; Dolstra H
    Hum Vaccin Immunother; 2014; 10(4):896-910. PubMed ID: 24335570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies.
    Swan D; Routledge D; Harrison S
    Br J Haematol; 2022 Feb; 196(3):488-506. PubMed ID: 34472091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current status and challenges of immunotherapy for multiple myeloma].
    Lu J; Bi JY
    Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):468-472. PubMed ID: 38317358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging immune targets for the treatment of multiple myeloma.
    Sohail A; Mushtaq A; Iftikhar A; Warraich Z; Kurtin SE; Tenneti P; McBride A; Anwer F
    Immunotherapy; 2018 Feb; 10(4):265-282. PubMed ID: 29421983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents.
    Madduri D; Dhodapkar MV; Lonial S; Jagannath S; Cho HJ
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):537-544. PubMed ID: 31427259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
    Hong S; Li H; Qian J; Yang J; Lu Y; Yi Q
    Clin Exp Immunol; 2012 Nov; 170(2):167-77. PubMed ID: 23039887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.